Teva Pharmaceutical Industries Limited (TEVA)
After hours:
| Previous close | 18.01 |
| Open | 18.02 |
| Bid | 18.01 x 1800 |
| Ask | 18.49 x 2200 |
| Day's range | 17.97 - 18.41 |
| 52-week range | 8.06 - 19.08 |
| Volume | |
| Avg. volume | 8,837,304 |
| Market cap | 20.857B |
| Beta (5Y monthly) | 0.88 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | 27 Nov 2017 |
| 1y target est | N/A |
- Simply Wall St.
Teva Pharmaceutical Industries Limited (NYSE:TEVA) is favoured by institutional owners who hold 68% of the company
Key Insights Significantly high institutional ownership implies Teva Pharmaceutical Industries' stock price is...
- Zacks
TEVA Stock Rises 72.5% This Year: Time to Buy, Sell or Hold?
Teva's reasonable valuation, an improving pipeline and the prospect of growth in sales and profits are good enough reasons for those who own the stock to stay invested.
- Reuters
Baltimore settles with Teva, Walgreens ahead of scheduled opioid trial
Baltimore said on Tuesday that it has settled with Walgreens over claims that the pharmacy operator fueled opioid addiction in the Maryland city, the latest in a series of settlements totaling $402.5 million ahead of a trial scheduled to begin next week. The announcement came a day after the city reached an $80 million settlement over opioids with drugmaker Teva Pharmaceutical. Baltimore did not disclose the terms of its settlement with Walgreens, but the cumulative settlement amount implies that it was also $80 million.
